Bicycle Therapeutics plc Capital Expenditures Incurred but Not yet Paid
Bicycle Therapeutics plc (BCYC) reported Capital Expenditures Incurred but Not yet Paid of $1.56 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2023-02-28
- Bicycle Therapeutics plc capital expenditures incurred but not yet paid for the quarter ending 2022-12-31 was $1.25M, a 4692.31% increase year-over-year.
- Bicycle Therapeutics plc capital expenditures incurred but not yet paid for the quarter ending 2022-09-30 was -$891.00K, a 440.08% decline year-over-year.
- Bicycle Therapeutics plc capital expenditures incurred but not yet paid for the quarter ending 2021-12-31 was $26.00K.
- Bicycle Therapeutics plc capital expenditures incurred but not yet paid for the quarter ending 2021-09-30 was $262.00K.
- Bicycle Therapeutics plc capital expenditures incurred but not yet paid for fiscal 2022 was $1.56M, a 382.72% increase from fiscal 2021.
- Bicycle Therapeutics plc capital expenditures incurred but not yet paid for fiscal 2021 was $324.00K, a 197.25% increase from fiscal 2020.
- Bicycle Therapeutics plc capital expenditures incurred but not yet paid for fiscal 2020 was $109.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2022-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $355.00K derived: sum of 2 quarters · filed 2023-02-28 | $1.56M 10-K · filed 2023-02-28 | |
| 2022-09-30 | -$891.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $318.00K 10-Q · filed 2022-11-03 | ||
| 2022-06-30 | $1.21M 10-Q · filed 2022-08-04 | |||
| 2021-12-31 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $288.00K derived: sum of 2 quarters · filed 2023-02-28 | $324.00K 10-K · filed 2023-02-28 | |
| 2021-09-30 | $262.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $298.00K 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $36.00K 10-Q · filed 2022-08-04 | |||
| 2020-12-31 | $109.00K 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |